JP2023508250A - 軽度外傷性脳損傷の処置 - Google Patents

軽度外傷性脳損傷の処置 Download PDF

Info

Publication number
JP2023508250A
JP2023508250A JP2022564096A JP2022564096A JP2023508250A JP 2023508250 A JP2023508250 A JP 2023508250A JP 2022564096 A JP2022564096 A JP 2022564096A JP 2022564096 A JP2022564096 A JP 2022564096A JP 2023508250 A JP2023508250 A JP 2023508250A
Authority
JP
Japan
Prior art keywords
ghrelin
variant
days
mtbi
symptoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022564096A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023508250A5 (cg-RX-API-DMAC10.html
Inventor
バンサル，ビシャル
シャー，カルティ
ワイアンド，マイケル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxeia Biopharmaceuticals Inc
Original Assignee
Oxeia Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxeia Biopharmaceuticals Inc filed Critical Oxeia Biopharmaceuticals Inc
Publication of JP2023508250A publication Critical patent/JP2023508250A/ja
Publication of JP2023508250A5 publication Critical patent/JP2023508250A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022564096A 2019-12-23 2020-12-22 軽度外傷性脳損傷の処置 Pending JP2023508250A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962953130P 2019-12-23 2019-12-23
US62/953,130 2019-12-23
PCT/US2020/066703 WO2021133844A1 (en) 2019-12-23 2020-12-22 Treatment of mild traumatic brain injury

Publications (2)

Publication Number Publication Date
JP2023508250A true JP2023508250A (ja) 2023-03-01
JP2023508250A5 JP2023508250A5 (cg-RX-API-DMAC10.html) 2024-01-04

Family

ID=76575665

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022564096A Pending JP2023508250A (ja) 2019-12-23 2020-12-22 軽度外傷性脳損傷の処置

Country Status (11)

Country Link
US (1) US20230031262A1 (cg-RX-API-DMAC10.html)
EP (1) EP4081238A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023508250A (cg-RX-API-DMAC10.html)
KR (1) KR20220122691A (cg-RX-API-DMAC10.html)
CN (1) CN114980915A (cg-RX-API-DMAC10.html)
AU (1) AU2020412765A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022012365A2 (cg-RX-API-DMAC10.html)
CA (1) CA3165738A1 (cg-RX-API-DMAC10.html)
IL (1) IL294156A (cg-RX-API-DMAC10.html)
MX (1) MX2022007844A (cg-RX-API-DMAC10.html)
WO (1) WO2021133844A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220370804A1 (en) * 2021-01-22 2022-11-24 The Regents Of The University Of Colorado, A Body Corporate Motor learning and vagus nerve stimulation (vns) paired with motor learning to treat demyelinating diseases, conditions and disorders
CN113723530B (zh) * 2021-09-02 2022-03-25 中国科学院自动化研究所 基于视频分析和电子心理沙盘的智能心理评估系统
US20260077018A1 (en) * 2022-09-07 2026-03-19 Oxeia Biopharmaceuticals, Inc. Treatment of mild traumatic brain injury

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016537173A (ja) * 2013-11-15 2016-12-01 ニューラル・アナリティクス・インコーポレーテッド 神経学的状態の診断のための脳の血流速度の構造的特徴をモニタリングすること
JP2017506625A (ja) * 2014-02-05 2017-03-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 軽度脳損傷の治療方法
WO2017075535A1 (en) * 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1231413A1 (zh) * 2014-04-29 2017-12-22 Teva Pharmaceutical Industries Ltd. 用於治疗具有高残疾状况的复发-缓解型多发性硬化症(rrms)的患者的拉喹莫德
CA2961889A1 (en) * 2014-08-19 2016-02-25 Oxeia Biopharmaceuticals, Inc. Methods of treating mild brain injury
US20180028617A1 (en) * 2015-02-19 2018-02-01 The Regents Of The University Of California Methods of treating mild brain injury and post-traumatic stress disorder
WO2016144978A1 (en) * 2015-03-09 2016-09-15 Oxeia Biopharmaceuticals, Inc. Methods of treating cognitive impairments or dysfunction

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016537173A (ja) * 2013-11-15 2016-12-01 ニューラル・アナリティクス・インコーポレーテッド 神経学的状態の診断のための脳の血流速度の構造的特徴をモニタリングすること
JP2017506625A (ja) * 2014-02-05 2017-03-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 軽度脳損傷の治療方法
WO2017075535A1 (en) * 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CELL TRANSPLANTATION, vol. Vol.26(7), JPN6025045127, 2017, pages 1131 - 1155, ISSN: 0005722570 *
PEPTIDES, vol. 54, JPN6025000112, 2014, pages 180 - 185, ISSN: 0005722571 *

Also Published As

Publication number Publication date
MX2022007844A (es) 2022-09-07
US20230031262A1 (en) 2023-02-02
CN114980915A (zh) 2022-08-30
BR112022012365A2 (pt) 2022-08-30
IL294156A (en) 2022-08-01
KR20220122691A (ko) 2022-09-02
CA3165738A1 (en) 2021-07-01
AU2020412765A1 (en) 2022-07-14
WO2021133844A1 (en) 2021-07-01
EP4081238A1 (en) 2022-11-02
EP4081238A4 (en) 2023-08-30

Similar Documents

Publication Publication Date Title
Obermann et al. Safety and efficacy of prednisone versus placebo in short-term prevention of episodic cluster headache: a multicentre, double-blind, randomised controlled trial
Busse et al. Liberty Asthma QUEST: phase 3 randomized, double-blind, placebo-controlled, parallel-group study to evaluate dupilumab efficacy/safety in patients with uncontrolled, moderate-to-severe asthma
Brown et al. Ant venom immunotherapy: a double-blind, placebo-controlled, crossover trial
Vermersch et al. Tetrahydrocannabinol: cannabidiol oromucosal spray for multiple sclerosis-related resistant spasticity in daily practice
Feil et al. Safety and efficacy of acetyl-DL-leucine in certain types of cerebellar ataxia: the ALCAT randomized clinical crossover trial
Rose et al. Treatment for inclusion body myositis
KR20220122691A (ko) 경도 외상성 뇌 손상의 치료
Inoue et al. Adverse reactions to BNT162b2 mRNA COVID-19 vaccine in medical staff with a history of allergy
Hallas et al. Methodological analysis: randomized controlled trials for pfizer and moderna COVID-19 vaccines
Singappuli et al. Antipsychotic long-term treatment in children and young people: a systematic review and meta-analysis of efficacy and tolerability across mental health and neurodevelopmental conditions
Buta et al. Real-world evidence of allergen immunotherapy
Attallah et al. Efficacy, safety and quality of life of oxybutynin versus aluminum chloride hexahydrate in treating primary palmar hyperhidrosis
Mohammed et al. Side effects associated with homologous and heterologous COVID-19 vaccines: a cross-sectional study in Saudi Arabia
Kwon et al. Acupuncture for sequelae of Bell's palsy: a randomized controlled trial protocol
US20260077018A1 (en) Treatment of mild traumatic brain injury
HK40080092A (en) Treatment of mild traumatic brain injury
Khokhar et al. Vaccination counseling with and without excipient skin testing in patients with suspected allergic reactions to mRNA COVID-19 vaccines and patients with atopy
Yaeger et al. Ropivacaine intramuscular paracervical injections for pediatric headache: a randomized placebo-controlled trial
Vázquez-Doce et al. Effectiveness of repeated injections of botulinum toxin A on gait and fatigue in adults with spastic paraparesis secondary to multiple sclerosis
JP2026506974A (ja) シャルコー・マリー・トゥース病を処置するための組成物及び方法
Kavya et al. Efficacy of nebulised dexmedetomidine versus aminophylline for treatment of postdural puncture headache in patients undergoing subarachnoid block posted for caesarean section: a double-blind, randomised controlled study
Kim et al. Herbal medicine (Kyungok-go) for fatigue in Long COVID patients: A prospective multicenter pilot study
Al Al Hamoud et al. Impact of Immunotherapy on Refractory Allergic Rhinitis in Armed Force Hospital Southern Region, Saudi Arabia
Leggio Efficacy of Rimegepant Plus Calcitonin Gene-Related Peptide Monoclonal Antibody for Migraine
Probasco Is Sildenafil Citrate Effective in Treating Erectile Dysfunction Secondary to Upper Motor Neuron Spinal Cord Injury?

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231221

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250114

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250401

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250613

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250710

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260402

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260602